SEC Filing Summary: Xenomics, Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K Current Report was filed by Xenomics, Inc. on March 8, 2005, covering events occurring on March 2, 2005. The registrant is incorporated in Florida with principal executive offices in New York, New York. Note: The request metadata referenced "Cardiff Oncology, Inc.," but the filing text explicitly identifies the registrant as Xenomics, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and contains no financial statements or performance data.
Material Changes
The primary material change reported is the departure of a principal officer:
- Christoph Bruening resigned as Secretary and Treasurer of Xenomics, Inc. effective March 2, 2005.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The document is limited to the notification of the officer's resignation.
Investor Verification Checklist
- Verify the identity of the registrant (Xenomics, Inc.) versus the metadata reference (Cardiff Oncology, Inc.).
- Confirm the appointment of a new Secretary and Treasurer to replace Christoph Bruening.
- Review subsequent filings for any financial impact or strategic changes resulting from this leadership transition.